Good Manufacturing Practice-Compliant Production and Lot-Release of Ex Vivo Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders

Good Manufacturing Practice-Compliant Production and Lot-Release of Ex Vivo Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders

In recent years, the exploration of regulatory T cell (Treg)-based cellular therapy has become an attractive strategy to ameliorate inflammation and autoimmunity in various clinical settings. The main obstacle to the clinical application of Treg in human is their low number circulating in peripheral...

Full description

Bibliographic Details
Main Authors: Manuel Wiesinger, Diane Stoica, Susanne Roessner, Carmen Lorenz, Anika Fischer, Raja Atreya, Clemens F. Neufert, Imke Atreya, Alexander Scheffold, Beatrice Schuler-Thurner, Markus F. Neurath, Gerold Schuler, Caroline J. Voskens
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-10-01
Series:Frontiers in Immunology
Subjects:
regulatory T cell
good manufacturing practice
autoimmunity
expansion
lot-release
Online Access:http://journal.frontiersin.org/article/10.3389/fimmu.2017.01371/full

Internet

http://journal.frontiersin.org/article/10.3389/fimmu.2017.01371/full

Similar Items